The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

The Food and Drug Administration on Friday cleared ... has now been specifically approved for patients with both obesity and moderate-to-severe obstructive sleep apnea, or OSA, a condition ...

CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...